A Follow-up Study to Evaluate the Long-term Post Treatment Effects of Peginterferon Alfa-2a (PEG-IFN) in Patients With HBeAg Positive Chronic Hepatitis B From the Original Study WV19432 (NEPTUNE).
Phase of Trial: Phase IV
Latest Information Update: 17 Apr 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms SON of NEPTUNE
- Sponsors Roche
- 07 Jun 2017 Biomarkers information updated
- 17 Apr 2016 Results (n=383) assessing HBeAg seroconversion (SC) rates 5 years after completion of treatment were presented at The International Liver Congress™ 2016.
- 10 Feb 2016 Treatment arm (from 1 to 4), design keyword (randomised & parallel), inclusion and exclusion criteria have been changed, as reported by ClinicalTrial.gov record.